Cathy Barrick • December 31, 2025

FDA Issues Correction for Continuous Glucose Monitoring Software

Author

Cathy Barrick

Date

December 31, 2025

Share

Dexcom Issues Correction for Dexcom G6 and G6 Pro Software:

This recall involves correcting devices and does not involve removing the devices from where they are used or sold. The FDA has identified this recall as the most serious type. This device may cause serious injury or death if you continue to use it without correction.


Affected Product

  • Product Name: Dexcom G6 Continuous Glucose Monitoring System G6 and G6 Pro Android US CGM App, Version 1.15.0
  • This correction only affects users of v.1.15.0 of the Android US App and does not apply to other users. All affected devices have been updated to resolve this issue.
  • Unique Device Identifier (UDI): SW11678: 00386270000811


What to Do
Upgrade from app version 1.15.0 as soon as possible.


On September 18, Dexcom Inc. sent all affected customers an Urgent Medical Device Correction message recommending the following actions:

  • Upgrade from app version 1.15.0 as soon as possible.
  • Open App Store and search for Dexcom G6 app.
  • Install latest Dexcom G6 app version.
  • Open Dexcom G6 app.
  • Contact Technical Support at 1-844-478-1600 for further assistance.
  • Users will no longer be able to use app version 1.15.0 after October 6, 2025.


Reason for Correction
Dexcom Inc. is correcting the Dexcom G6 Continuous Glucose Monitoring System’s G6 and G6 Pro Android US CGM App version 1.15.0 due to an identified bug that can cause the app to terminate unexpectedly. As a result, the user may not receive estimated glucose values, alarms, or alerts. If a user is unaware that the app has terminated, there is potential for missed detection of a high blood sugar (hyperglycemic) or low blood sugar (hypoglycemic) event.


The use of affected product may cause serious adverse health consequences, including hyperglycemia, hypoglycemia, and death.


As of September 16, Dexcom has not reported any serious injuries or deaths associated with this issue.


Device Use
The Dexcom G6 Continuous Glucose Monitoring System is a real-time continuous glucose monitoring system that sends glucose readings to a compatible smart device or the Dexcom receiver every five minutes. The Dexcom G6 and G6 Pro Android US CGM App is an application for compatible smart devices that displays glucose levels and trends.


Contact Information
Customers in the U.S. with questions about this recall should contact Dexcom Technical Support at 1-844-478-1600.


Additional FDA Resources


Unique Device Identifier (UDI)
The unique device identifier (UDI) helps identify individual medical devices sold in the United States from manufacturing through distribution to patient use. The UDI allows for more accurate reporting, reviewing, and analyzing of adverse event reports so that devices can be identified, and problems potentially corrected more quickly.


How do I report a problem?
Health care professionals and consumers may 
report adverse reactions or quality problems they experienced using these devices to MedWatch: The FDA Safety Information and Adverse Event Reporting Program.

PA ODP logo with dark blue border
By Tim Sohosky May 29, 2026
On Thursday, May 28, the Office of Developmental Programs (ODP) provided an update to the Medical Assistance Advisory Committee (MAAC) regarding current policies and upcoming regulatory changes following a recent Commonwealth Court decision. On February 17, 2026, the PA Commonwealth Court issued a decision in Dunkelberger v. Department of Human Services that determined that ODP’s limitations on provider model services (specifically the 40/60-hour caps and 90-day travel maximums) were null and void. The decision was based on process rather than policy validity; the Court found that these limitations were not properly promulgated as regulations in accordance with the Commonwealth Documents Law and Regulatory Review Act. To maintain a balanced approach between flexibility and oversight, ODP is moving forward with the following actions: Regulatory Amendments: ODP will amend regulations to establish formal authority for setting service delivery limits that support individual welfare and program integrity. Self-Directed Model Agreements: ODP has already modified agreements for self-directed models to clarify limits on overtime, combined relative service provision, and travel restrictions. Travel Restrictions: Due to the inability to monitor services effectively over long distances, service provision will now be limited to Pennsylvania and contiguous states. Waiver Changes: ODP will seek modifications through the amendment process to the Consolidated, P/FDS, Community Living, and Adult Autism Waivers to include: New requirements for agencies providing IHCS and Companion services to disclose a DSP's relationship to participants; and Strengthened programmatic oversight and integrity measures. Life Sharing Alternative: For participants requiring more than 60 hours of paid care from a relative, the Life Sharing (24/7) service model remains the recommended alternative. ODP anticipates a public comment period for these proposed waiver changes beginning in January 2027.
Yellow screen with the words
By Cathy Barrick May 28, 2026
The Office of Developmental Programs (ODP) has shared ODPANN 26-039 . The purpose of this communication is to provide updated details about the Residential Performance-Based Contracting (PBC) Pay-for-Performance (P4P) initiatives for Fiscal Year 2026/27. Updates are provided in red . Please review the announcement for more details. Visit here to access the Pay for Performance (P4P): Residential Rural Capacity Expansion Plan template .